Caesar Luo News Today

Eight-year-old Asa, who was caught in the crossfire of a freeway shooting in Oakland, is now paralyzed, his family said, and despite the medical care that he'll likely need for the rest of his life, he continues to make them laugh.

Asa Luo is the third child to have been hit by stray bullets on Bay Area freeways in recent years

Eight-year-old Asa, who was caught in the crossfire of a freeway shooting in Oakland, is now paralyzed, his family said, and despite the medical care that he'll likely need for the rest of his life, he continues to make them laugh.

An 8-year-old boy was paralyzed after he was shot by a stray bullet on an Oakland freeway. The shooting: Asa Luo was riding in his family’s car on Interstate-580 near the Harrison Street exit when their vehicle was caught in a crossfire between two other vehicles that started shooting at each other on July 14. Luo was immediately rushed to the Oakland Children’s Hospital in critical condition.

Eight-year-old Asa, who was caught in the crossfire of a freeway shooting in Oakland, is now paralyzed, his family said, and despite the medical care that he'll likely need for the rest of his life, he continues to make them laugh.

Eight-year-old Asa, who was caught in the crossfire of a freeway shooting in Oakland, is now paralyzed, his family said, and despite the medical care that he'll likely need for the rest of his life, he continues to make them laugh.

Eight-year-old Asa Luo, who was caught in the crossfire of a freeway shooting in Oakland, is now paralyzed, his family said, and despite the medical care that he'll likely need for the rest of his life, he continues to make them laugh.

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.